Evidence map›Paper›PMID 36422493›Full record

ArticleTurkish journal of medical sciences2022

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.

Fatih Gürler, Deniz Can Güven, Ergin Aydemir, Osman Sütçüoğlu, Bediz Kurt İnci, Zafer Arık, Şuayib Yalçın, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Fatih GürlerDepartment of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Deniz Can GüvenDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ergin AydemirDepartment of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey.
Osman SütçüoğluDepartment of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Bediz Kurt İnciDepartment of Medical Oncology, Aksaray Training and Research Hospital, Aksaray, Turkey.
Zafer ArıkDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Şuayib YalçınDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Nuriye ÖzdemirDepartment of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Ahmet ÖzetDepartment of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Ozan YazıcıDepartment of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Gazi University · TRAnkara Onkoloji Eğitim ve Araştırma Hastanesi · TRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF) regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment.

methodsThe medical records of 72 patients were retrospectively reviewed. Survivals and hematological adverse events of the patients were examined. Factors affecting survivals were analyzed in univariate analysis. A multivariate analysis was performed with the factors contributing to survivals in univariate analysis.

resultsThe median PFS (mPFS) was 10.1 months (95% CI, 6.8-13.4) in the FLOT arm (n = 33) and 7.4 months (95% CI, 9.1-21.6) in the mDCF arm (n = 39) (p = 0.041). The median OS (mOS) was 12.9 months (95% CI, 9.7-16.1) in the FLOT arm and 15.4 months (95% CI, 9.1-21.6) in the mDCF arm (p = 0.622). It was found that all grade neutropenia was 51.3% vs. 72.7% (p = 0.063), febrile neutropenia was 8.3% vs. 6.3% (p = 0.743), and thrombocytopenia was 48.7% vs. 51.5% (p = 0.813) in the FLOT and mDCF arms, respectively. Anemia was 59% in the FLOT arm and 100% in the mDCF arm (p < 0.001). Grade 3-4 anemia was 7.7% in the FLOT arm and 24.2% in the mDCF arm (p = 0.052). DISCUSSION: It was shown that the mPFS was significantly increased in the FLOT arm compared to the mDCF arm as the first-line treatment in patients with metastatic GC and GEJC. Hematological adverse events were more favorable in the FLOT arm than in the mDCF arm.

Indexed as

AdenocarcinomaStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelEsophageal NeoplasmsFluorouracilHumansRetrospective StudiesTaxoidsCisplatinDocetaxelFluorouracilTaxoidsFLOTgastric cancergastroeosephageal cancermodified DCF

Identifiers

PMID36422493
PMCPMC10395706
OpenAlexW4310331176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.